Natalizumab for multiple sclerosis: the dilemma of NOVA

Affiliations

Comment

Kerstin Hellwig. Lancet Neurol. 2022 Jul.

. 2022 Jul;21(7):579-581.

doi: 10.1016/S1474-4422(22)00170-3. Epub 2022 Apr 25.

¹ Department of Neurology, Katholisches Klinikum Bochum, Bochum 44791, Germany. Electronic address: kerstin.hellwig@rub.de.

No abstract available

Comment on

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.